DexCom Inc
DXCM: XNAS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$29.00 | Bvkh | Qlfmgslrn |
Dexcom Buoyed by Penetration of Type 2 Market; Raising Our Fair Value Estimate
Business Strategy and Outlook
Dexcom enjoys a well-established track record for introducing the most precise sensors for use in its continuous glucose monitors. On the strength of its technology, Dexcom has captured an impressive slice of this CGM market, but a recent wave of innovation in the diabetes device market has introduced new competitive pressure. Nonetheless, Dexcom has done a credible job of adapting and fending off competition from Abbott and Medtronic.